Fibrous dysplasia (FD) is a mosaic disease caused by a mutation in the gene GNAS1 that leads to fibro-osseous tissue growth in place of normal bone, prone to deformity, fractures, and pain. Lesions expand during childhood, usually reaching the final burden by the age of 15 years. There is currently no curative treatment, but antiresorptive therapies that inhibit osteoclast function, like denosumab and bisphosphonates, are being studied. However, there are no clear guidelines for the dosage and scheduling that each patient should receive. Hence, the development of mathematical models to study the disease in silico can be a great advantage and may aid medical decision-making in FD.